Ipamorelin dosage, as it appears in the studies

Read this first

This page reports doses from published studies. It is not a protocol and not advice. No line here tells anyone to take anything. Every figure is what a study administered, to which species, by which route — third person, on purpose.

Most ipamorelin dosing data is from rats. The human numbers come from two studies only: a pharmacokinetic study using IV infusions, and a Phase 2 surgical trial dosing 0.03 mg/kg IV twice daily. There is no validated human dose for any wellness, fat-loss, or muscle goal, because no trial established one. The community subcutaneous routines paired with CJC-1295 have no peer-reviewed human dosing basis and are described below as anecdote, not a recommendation.

Doses used in studies

Reported research doses, by context:

• Human pharmacokinetics: 4.21-140.45 nmol/kg IV over 15 minutes, single doses ^[6].
• Human Phase 2 ileus trial: 0.03 mg/kg IV twice daily, up to 7 days ^[5].
• Rat bone growth: 18, 90, 450 microg/day SC, split three times daily, 15 days ^[1].
• Rat bone mineral: 0.5 mg/kg/day continuous SC by osmotic minipump, 12 weeks ^[2].
• Rat glucocorticoid rescue: 100 microg/kg SC three times daily, 3 months ^[3].
• Rat postoperative ileus: 0.1-1 mg/kg IV, four times daily ^[10].
• Ferret cachexia (2024): 1-3 mg/kg intraperitoneal ^[14].

These span a wide range because they chase different endpoints in different animals. They do not convert into a human dose.

Half-life and timing

In healthy human volunteers, ipamorelin's terminal half-life is about 2 hours (IV), with clearance 0.078 L/h/kg and steady-state volume of distribution 0.22 L/kg ^[6]. The growth-hormone response is a single discrete pulse peaking near 40 minutes (0.67 h) after dosing ^[6]. (Half-life = time for blood level to drop by half. Terminal = the slow elimination phase.)

In rats, plasma clearance runs roughly 5-fold lower than GHRP-6 ^[4]. The short half-life and single-pulse kinetics are why community protocols dose around sleep or training — but that timing logic is not validated by any human outcome trial.

Routes studied

Ipamorelin has been given by several routes in research:

• Intravenous — human pharmacokinetics and the clinical trial; rodent efficacy.
• Subcutaneous — the rodent bone and body-composition studies; the dominant route in off-label community use.
• Intranasal — rat pharmacokinetics, roughly 20% bioavailability.
• Intraperitoneal — rodent and ferret efficacy studies.

Ipamorelin itself is not orally bioavailable; only engineered ipamorelin-derived analogs achieved oral activity (about 10% in dogs).

How much cjc-1295 ipamorelin should i take

There is no answer this page can give, because no controlled human trial established a dose for the cjc-1295 ipamorelin combination for any wellness outcome. The human ipamorelin doses on record are a research IV pharmacokinetic range and a 0.03 mg/kg IV surgical-trial dose ^[6][5] — neither is a subcutaneous wellness protocol. The CJC-1295 human data used 30-60 microg/kg subcutaneously in a study of that agent alone ^[12]. Community microgram routines exist but rest on no peer-reviewed human dosing basis. This site reports the research; it does not prescribe.

How to reconstitute cjc-1295 ipamorelin 5mg

Reconstitution is a handling step, not a dosing instruction, and the research-supply literature treats it generally. Ipamorelin ships as a lyophilized (freeze-dried) powder — free base or acetate salt — and is reconstituted with bacteriostatic water for research handling ^[6]. As a peptide it degrades with heat and repeated freeze-thaw, so reconstituted solution is typically kept refrigerated. These are general peptide-handling observations, not a clinical preparation method, and nothing here specifies an amount to administer to a person.